Novo Nordisk's shares [NYSE: NVO] fell 5.6% yesterday after the Danish pharmaceutical firm said its oral semaglutide, the active ingredient of its popular diabetes and weight-loss drugs Ozempic and Wegovy, failed to slow the progression of Alzheimer’s disease.